General Callout
Nunc dolor esse suscipit eros eros ullamco dolor. Duis velaliquam sunt urna, tempuribud doming quis, laboris ultricies ultricies urna laboris. Nostrud pulvinar nostrud elit sunt ex exercitation magna tempuribud laboris ea ex nunc sed exercitation ea laboris dignissim.
Accordion
Quis harmud ea commodo voluptate dolor urna providerent tempor amet dignissim velit consectetur harmud sint doming, urna magna velit sed commodo urna sint sunt nunc. Nunc consectetur laboris harmud dolore exercitation sed magna laboris nulla velit velaliquam ultricies. Dignissim adipiscing, sed duis ultricies sint voluptate providerent nunc nisi.
Heading 1
Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.
Heading 2
Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.
Call to action
Esse suscipit in eros ea sed voluptate dolore, harmud nisi, dolore ultricies fugiat amet doming ut sint ut adipiscing. Sit velit velaliquam ex nunc ut voluptate
Dysport Therapeutic (abobotulinumtoxina)
Status:
Concluded with an LOI
Manufacturer:
Ipsen Biopharmaceuticals Canada, Inc.
Indication:
Upper Limb Spasticity
Last updated July 17, 2018
Dysport Therapeutic (abobotulinumtoxina)
Status:
Concluded with an LOI
Manufacturer:
Ipsen Biopharmaceuticals Canada, Inc.
Indication:
Cervical dystonia
Last updated July 17, 2018
Hemangiol (propranolol oral solution)
Status:
Concluded with an LOI
Manufacturer:
Pierre Fabre
Indication:
Infantile hemangioma
Last updated July 16, 2018
Status:
Concluded with an LOI
Manufacturer:
Novartis Pharmaceuticals Canada Inc.
Indication:
Acute Myeloid Leukemia (AML)
Last updated July 5, 2018
Status:
Concluded with an LOI
Manufacturer:
Intercept Pharma Canada
Indication:
Primary biliary cholangitis
Last updated June 27, 2018
Descovy (emtricitabine/tenofovir alafenamide)
Status:
Concluded without agreement
Manufacturer:
Gilead Sciences Canada Inc.
Indication:
HIV-1 Infection
Last updated June 8, 2018
Odefsey (emtricitabine/rilpivirine/tenofovir alafenamide)
Status:
Concluded with an LOI
Manufacturer:
Gilead Sciences Canada Inc.
Indication:
HIV-1 Infection
Last updated June 6, 2018
Status:
Concluded with an LOI
Manufacturer:
Sanofi Genzyme Canada
Indication:
Medullary Thyroid Cancer
Last updated June 1, 2018
Status:
Concluded without agreement
Manufacturer:
Sanofi Genzyme Canada
Indication:
Gaucher disease
Last updated May 31, 2018
Status:
Concluded without agreement
Manufacturer:
Sanofi Genzyme Canada
Indication:
Gaucher disease
Last updated May 31, 2018